{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:52:54Z","timestamp":1792518774616,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prohibiting the sale of commonly preferred e-cigarette flavors (eg, fruity and sweet) to discourage use among youths poses a risk of diminishing efforts to decrease smoking in adults.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare reductions in smoking achieved in adults with psychiatric conditions or lower educational level using very low nicotine content (VLNC) cigarettes alone, combined with e-cigarettes limited to tobacco flavor (TF), or combined with e-cigarettes in participant-preferred flavors.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Three randomized clinical trials were conducted for 16 weeks from October 2020 through November 2023 at the University of Vermont, Brown University, and Johns Hopkins University. Participants were adults who smoked daily and were not planning to quit in the next 30 days. These participants were from 3 at-risk populations: those with affective disorders, exemplifying mental illness; those with opioid use disorder, exemplifying substance use disorders; and females of reproductive age with a high-school education or less, exemplifying lower educational level. Participants were randomly assigned to 1 of 4 experimental conditions: (1) normal nicotine content (NNC) cigarettes only; (2) VLNC cigarettes only; (3) VLNC cigarettes plus e-cigarettes with classic TF (hereafter, VLNC + TF); and (4) VLNC cigarettes plus e-cigarettes with preferred flavors (hereafter, VLNC + PF).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The NNC cigarettes contained 15.8 mg nicotine\/g tobacco, the VLNC cigarettes contained 0.4 mg nicotine\/g tobacco, the VLNC\u2009+\u2009TF had pods containing 5% nicotine by weight and only classic TF, and the VLNC + PF had pods containing 5% nicotine in 8 flavors (including fruity and sweet) from which participants selected 3 flavors.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was mean total cigarettes smoked per day (CPD) during week 16. Tobacco-related biomarkers were assessed, including total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a tobacco-specific carcinogen.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 326 participants (mean [SD] age, 40.09 [10.79] years; 243 females [74.5%]) from 3 randomized clinical trials were included. The VLNC cigarettes decreased total CPD, with least square (LS) means (SEMs) of 22.54 (1.59) in the NNC, 14.32 (1.32) in the VLNC, 11.76 (1.18) in the VLNC + TF, and 7.63 (0.90) in the VLNC + PF conditions. Each VLNC condition differed significantly from NNC, with an adjusted mean difference (AMD) of \u22128.21 (95% CI, \u221212.27 to \u22124.16;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) in the VLNC, \u221210.78 (95% CI, \u221214.67 to \u22126.90;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) in the VLNC + TF, and \u221214.91 (95% CI, \u221218.49 to \u221211.33;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) in the VLNC + PF conditions. Participants in the VLNC + PF condition also decreased smoking below the VLNC and the VLNC + TF conditions (AMDs, \u22126.70 [95% CI, \u22129.84 to \u22123.55;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001] and \u22124.13 [95% CI, \u22127.05 to \u22121.21;\n P<\/jats:italic>\n \u2009=\u2009.02]); the VLNC and VLNC + TF conditions did not differ significantly. Consistent with decreases in CPD, NNAL levels in the VLNC + PF condition were lower than in all other conditions, with AMDs (in pmol\/mg creatinine) of \u22120.94 (95% CI, \u22121.41 to \u22120.47;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) compared with the NNC condition, \u22120.47 (95% CI, \u22120.87 to \u22120.08;\n P<\/jats:italic>\n \u2009=\u2009.03) compared with the VLNC condition, and \u22120.46 (95% CI, \u22120.83 to \u22120.10;\n P<\/jats:italic>\n \u2009=\u2009.04) compared with the VLNC + TF condition.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These results provide further evidence that a reduced-nicotine standard for cigarettes has the potential to decrease smoking and tobacco-toxicant exposure in high-risk populations and that these effects may be enhanced when adults can access e-cigarettes in commonly preferred flavors.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifiers:\n NCT04092387<\/jats:ext-link>\n ,\n NCT04090879<\/jats:ext-link>\n ,\n NCT04092101<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.31731","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:36:03Z","timestamp":1725622563000},"page":"e2431731","source":"Crossref","is-referenced-by-count":20,"title":["Reduced Nicotine Cigarettes and E-Cigarettes in High-Risk Populations"],"prefix":"10.1001","volume":"7","author":[{"given":"Stephen T.","family":"Higgins","sequence":"first","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey C.","family":"Sigmon","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W.","family":"Tidey","sequence":"additional","affiliation":[{"name":"Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Heil","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diann E.","family":"Gaalema","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"DeSarno","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias M.","family":"Klemperer","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Menson","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Cioe","sequence":"additional","affiliation":[{"name":"Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Plucinski","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon C.","family":"Wiley","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Orr","sequence":"additional","affiliation":[{"name":"University of Vermont Tobacco Center of Regulatory Science, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"zoi240953r2","doi-asserted-by":"publisher","DOI":"10.5888\/pcd19.220184","article-title":"Disparities in current cigarette smoking among US adults with mental health conditions.","volume":"19","author":"Loretan","year":"2022","journal-title":"Prev Chronic Dis"},{"issue":"Suppl 1","key":"zoi240953r3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.drugalcdep.2008.12.005","article-title":"Educational attainment and smoking among women: risk factors and consequences for offspring.","volume":"104","author":"Kandel","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"zoi240953r4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ypmed.2017.07.030","article-title":"Tobacco and nicotine delivery product use in a national sample of pregnant women.","volume":"104","author":"Kurti","year":"2017","journal-title":"Prev Med"},{"key":"zoi240953r5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ypmed.2018.03.001","article-title":"Tobacco and nicotine delivery product use in a U.S. national sample of women of reproductive age.","volume":"117","author":"Lopez","year":"2018","journal-title":"Prev Med"},{"key":"zoi240953r6","doi-asserted-by":"publisher","first-page":"h4065","DOI":"10.1136\/bmj.h4065","article-title":"Smoking cessation and reduction in people with chronic mental illness.","volume":"351","author":"Tidey","year":"2015","journal-title":"BMJ"},{"issue":"18","key":"zoi240953r8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJMsr1714617","article-title":"Potential public health effects of reducing nicotine levels in cigarettes in the United States.","volume":"378","author":"Apelberg","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240953r9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ntr\/nty200","article-title":"The future of nicotine regulation: key questions and challenges.","volume":"21","author":"Zeller","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"14","key":"zoi240953r10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMsa1502403","article-title":"Randomized trial of reduced-nicotine standards for cigarettes.","volume":"373","author":"Donny","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240953r11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2018.11473","article-title":"Effect of immediate vs gradual reduction in nicotine content of cigarette on biomarkers of smoke exposure: a randomized clinical trial.","volume":"320","author":"Hatsukami","year":"2018","journal-title":"JAMA"},{"key":"zoi240953r12","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/ntr\/ntz133","article-title":"etal. Effects of 6-week use of very low nicotine content cigarettes in smokers with serious mental illness.","volume":"21","author":"Tidey","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"10","key":"zoi240953r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.19311","article-title":"Changes in cigarette consumption with reduced nicotine content cigarettes among smokers with psychiatric conditions or socioeconomic disadvantage: 3 randomized clinical trials.","volume":"3","author":"Higgins","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi240953r14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/add.13534","article-title":"Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.","volume":"112","author":"Benowitz","year":"2017","journal-title":"Addiction"},{"issue":"12","key":"zoi240953r15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMp1707409","article-title":"A nicotine-focused framework for public health.","volume":"377","author":"Gottlieb","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi240953r18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/add.13603","article-title":"Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.","volume":"112","author":"Hatsukami","year":"2017","journal-title":"Addiction"},{"key":"zoi240953r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100796","article-title":"Reduced nicotine in cigarettes in a marketplace with alternative nicotine systems: randomized clinical trial.","volume":"35","author":"Hatsukami","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"Pt B","key":"zoi240953r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107213","article-title":"Preliminary evidence on cigarette nicotine reduction with concurrent access to an e-cigarette: Manipulating cigarette nicotine content, e-liquid nicotine content, and e-liquid flavor availability.","volume":"165","author":"White","year":"2022","journal-title":"Prev Med"},{"issue":"2","key":"zoi240953r22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.yrtph.2006.09.001","article-title":"Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany.","volume":"47","author":"Scherer","year":"2007","journal-title":"Regul Toxicol Pharmacol"},{"issue":"8","key":"zoi240953r23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1021\/tx400121n","article-title":"High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers.","volume":"26","author":"Carmella","year":"2013","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"zoi240953r24","first-page":"1668","article-title":"Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy.","volume":"11","author":"Jacob","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"zoi240953r25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/ntr\/ntz235","article-title":"Biomarkers of exposure for dual use of electronic cigarettes and combustible cigarettes: nicotelline, NNAL, and total nicotine equivalents.","volume":"22","author":"Jacob","year":"2020","journal-title":"Nicotine Tob Res"},{"issue":"9","key":"zoi240953r26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/add.1991.86.issue-9","article-title":"The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire.","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br J Addict"},{"issue":"5","key":"zoi240953r27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ntr\/ntq032","article-title":"Development of the brief Wisconsin inventory of smoking dependence motives.","volume":"12","author":"Smith","year":"2010","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi240953r28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14622200020032051","article-title":"Evaluation of the Brief Questionnaire of Smoking Urges (QSU-brief) in laboratory and clinical settings.","volume":"3","author":"Cox","year":"2001","journal-title":"Nicotine Tob Res"},{"issue":"3","key":"zoi240953r29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archpsyc.1986.01800030107013","article-title":"Signs and symptoms of tobacco withdrawal.","volume":"43","author":"Hughes","year":"1986","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"zoi240953r30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1037\/1064-1297.7.4.412","article-title":"Modeling drug consumption in the clinic using simulation procedures: demand for heroin and cigarettes in opioid-dependent outpatients.","volume":"7","author":"Jacobs","year":"1999","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"zoi240953r31","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1378\/chest.128.4.2528","article-title":"Effects of cigarette reduction on cardiovascular risk factors and subjective measures.","volume":"128","author":"Hatsukami","year":"2005","journal-title":"Chest"},{"issue":"6","key":"zoi240953r32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","article-title":"Development and validation of brief measures of positive and negative affect: the PANAS scales.","volume":"54","author":"Watson","year":"1988","journal-title":"J Pers Soc Psychol"},{"issue":"2","key":"zoi240953r33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1037\/0022-006X.59.2.295","article-title":"The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change.","volume":"59","author":"DiClemente","year":"1991","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"zoi240953r34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ntr\/nty046","article-title":"Development and validation of the Questionnaire of Vaping Craving.","volume":"21","author":"Dowd","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi240953r36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/acs.accounts.5b00472","article-title":"Exposure and metabolic activation biomarkers of carcinogenic tobacco-specific nitrosamines.","volume":"49","author":"Hecht","year":"2016","journal-title":"Acc Chem Res"},{"issue":"10","key":"zoi240953r39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9763","article-title":"Current advances in research in treatment and recovery: Nicotine addiction.","volume":"5","author":"Prochaska","year":"2019","journal-title":"Sci Adv"},{"issue":"7","key":"zoi240953r40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2011.300186","article-title":"Smoking cessation behavior among intermittent smokers versus daily smokers.","volume":"101","author":"Tindle","year":"2011","journal-title":"Am J Public Health"},{"key":"zoi240953r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102142","article-title":"Effect of unguided e-cigarette provision on uptake, use, and smoking cessation among adults who smoke in the USA: a naturalistic, randomised, controlled clinical trial.","volume":"63","author":"Carpenter","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi240953r42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa2308815","article-title":"Electronic nicotine-delivery systems for smoking cessation.","volume":"390","author":"Auer","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi240953r43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMe2314977","article-title":"Electronic cigarette for smoking cessation-have we reached a tipping point.","volume":"390","author":"Rigotti","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240953r44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/add.v118.9","article-title":"Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: guidance from the Cochrane Tobacco Addiction Group.","volume":"118","author":"Hartmann-Boyce","year":"2023","journal-title":"Addiction"},{"issue":"10","key":"zoi240953r45","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamapsychiatry.2017.2355","article-title":"Addiction potential of cigarettes with reduced nicotine content in populations with psychiatric disorders and other vulnerabilities to tobacco addiction.","volume":"74","author":"Higgins","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi240953r46","article-title":"Electronic cigarettes for smoking cessation.","volume":"1","author":"Lindson","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi240953r35","year":"2004"},{"key":"zoi240953r37","volume-title":"The Health Consequences of Smoking\u201450 Years of Progress: A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2014"},{"key":"zoi240953r38","volume-title":"Smoking Cessation: A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2020"},{"key":"zoi240953r1","unstructured":"Centers for Disease Control and Prevention. Health effects of cigarette smoking. Accessed November 24, 2023. https:\/\/www.cdc.gov\/tobacco\/data_statistics\/fact_sheets\/health_effects\/effects_cig_smoking\/index.htm#"},{"key":"zoi240953r7","unstructured":"US Food and Drug Administration. FDA News Release: FDA announces plans for proposed rule to reduce addictiveness of cigarettes and other combusted tobacco products. June 21, 2022. Accessed July 6, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plans-proposed-rule-reduce-addictiveness-cigarettes-and-other-combusted-tobacco"},{"key":"zoi240953r16","unstructured":"US Food and Drug Administration. Results from the Annual National Youth Tobacco Survey. Accessed November 25, 2023. https:\/\/www.fda.gov\/tobacco-products\/youth-and-tobacco\/results-annual-national-youth-tobacco-survey#:~:text=Among%20U.S.%20high%20school%20students,used%20e%2Dcigarettes%20in%202023"},{"key":"zoi240953r17","unstructured":"US Food and Drug Administration. FDA News Release: FDA finalizes enforcement policy on unauthorized flavored cartridge-based e-cigarettes that appeal to children, including fruit and mint. January 2, 2020. Accessed November 25, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-finalizes-enforcement-policy-unauthorized-flavored-cartridge-based-e-cigarettes-appeal-children"},{"key":"zoi240953r21","unstructured":"National Institute on Drug Abuse. Nicotine research cigarettes drug supply program. Accessed January 4, 2020. https:\/\/www.drugabuse.gov\/research\/research-data-measures-resources\/nicotine-research-cigarettenida-drug-supply-program"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823300\/higgins_2024_oi_240953_1724946489.31941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:36:14Z","timestamp":1725622574000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823300"}},"subtitle":["3 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.31731","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}